NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

25 Sep 2019 | News

Naarden, The Netherlands, 25 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases,...

NorthSea Therapeutics strengthens its management team with the appointment of Mats Blom as CFO

4 Sep 2019 | News

Naarden, The Netherlands, 4 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of...

Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells

9 Nov 2018 | News

Results to be presented at the AASLD congress 2018, 9-13 November In a biopsy-confirmed fibrotic ob/ob NASH mouse model, icosabutate reduced hepatic fibrosis in association with a 45% decrease in myofibroblast content in pre- versus post-treatment liver biopsies In a...

Potential of icosabutate as a novel approach to the treatment of NASH highlighted in late-breaker at The International Liver CongressTM 2018

12 Apr 2018 | News

Late breaker EASL Icosabutate, a structurally engineered fatty acid, displays optimised phamacokinetics for targeting both metabolic and inflammatory pathways in the liver, both with key relevance for NASH Pre-clinical data show broad and powerful pharmacodynamic...

NorthSea Therapeutics secures €25 million funding for clinical development of promising NASH drug

12 Dec 2017 | News

Lead drug icosabutate, in-licensed from Pronova BioPharma AS Phase IIb-ready at the end of 2018 Naarden, The Netherlands, 12 December 2017 – NorthSea Therapeutics B.V. (‘NST’), a newly established Dutch biotech company, announced today the completion of a €25m Series...